UK
-
University of Edinburgh’s Macrophage Cell Therapy slashes liver transplant need
Researchers tested the therapy through the MATCH clinical trial, which involved 50 patients with advanced liver cirrhosis.
-
Sentante secures CE mark for robotic endovascular surgery platform ahead of European rollout
Sentante’s platform enables clinicians to perform endovascular procedures remotely through a teleoperated workstation equipped with haptic feedback controls and multiple operating room displays.
-
Embecta expands drug delivery portfolio with US$172.6M Owen Mumford acquisition
Owen Mumford brings established expertise in device design, precision moulding, and medical device assembly, which will now be integrated with Embecta’s commercial infrastructure and large-scale manufacturing capabilities.
-
UK secures Japanese antiviral Favipiravir amid Hantavirus preparedness
The antiviral drug was originally designed to treat influenza but has also attracted attention for its potential activity against other RNA viruses.
-
AstraZeneca’s Imfinzi gains UK NHS approval for stomach cancer after NICE green light
NICE recommended Imfinzi for adults whose stomach cancer has not spread extensively and can be removed through surgery, including gastric and gastro-oesophageal junction cancers that physicians frequently diagnose at advanced stages.
-
GSK’s Efimosfermin receives dual fast-track designations for MASH treatment
The US Food and Drug Administration granted the therapy Breakthrough Therapy Designation, while the European Medicines Agency awarded it Priority Medicines status.
-
Bruker unveils MyGenius PRO molecular diagnostics system in Europe at ESCMID Global 2026
MyGenius PRO adds to Bruker’s molecular diagnostics portfolio, which includes InGenius, BeGenius, and LiquidArray assays.
-
Roche initiates new phase 3 trial to secure European approval for Elevidys
The European Medicines Agency rejected Elevidys for ambulatory patients last year, citing insufficient evidence of effectiveness.
-
UK’s MHRA approves single-injection 7.2mg Wegovy pen for obesity management
The approval specifically applies to adults diagnosed with obesity and does not extend to individuals who are overweight with a BMI below 30kg/m² using Wegovy for weight management.
-
Johnson & Johnson launches advanced Varipulse Pro Ablation System in Europe with CE Mark approval
Varipulse Pro will receive prominent visibility at the European Heart Rhythm Association (EHRA) annual meeting, where J&J plans to conduct live procedure demonstrations and offer practical training sessions for healthcare professionals.